Abstract:Microglia exhibit both maladaptive and adaptive roles in the pathogenesis of neurodegenerative diseases and have emerged as a cellular target for central nervous system (CNS) disorders, including those affecting the retina. Replacing maladaptive microglia, such as those impacted by aging or over-activation, with exogenous microglia that can enable adaptive functions has been proposed as a potential therapeutic strategy for neurodegenerative diseases. To investigate microglia replacement as an approach for retinal diseases, we first employed a protocol to efficiently generate human-induced pluripotent stem cells (hiPSC)-derived microglia in quantities sufficient for in vivo transplantation. These cells demonstrated expression of microglia-enriched genes and showed typical microglial functions such as LPS-induced responses and phagocytosis. We then performed xenotransplantation of these hiPSC-derived microglia into the subretinal space of adult mice whose endogenous retinal microglia have been pharmacologically depleted. Long-term analysis post-transplantation demonstrated that transplanted hiPSC-derived microglia successfully integrated into the neuroretina as ramified cells, occupying positions previously filled by the endogenous microglia and expressed microglia homeostatic markers such as P2ry12 and Tmem119. Further, these cells were found juxtaposed alongside residual endogenous murine microglia for up to eight months in the retina, indicating their ability to establish a stable homeostatic state in vivo. Following retinal pigment epithelial (RPE) cell injury, transplanted microglia demonstrated responses typical of endogenous microglia, including migration, proliferation, and phagocytosis. Our findings indicate the feasibility of microglial transplantation and integration in the retina and suggest that modulating microglia through replacement may be a therapeutic strategy for treating neurodegenerative retinal diseases.

Efficient Strategies for Microglia Replacement in the Central Nervous System

Efficient Strategies for Microglia Replacement in the Central Nervous System (vol 32, 108041-14.E1, 2020)

Microglia replacement by bone marrow transplantation (Mr BMT) in the central nervous system of adult mice

Treatment of a genetic brain disease by CNS-wide microglia replacement

Allogenic microglia replacement: A novel therapeutic strategy for neurological disorders

Protocol for Microglia Replacement by Peripheral Blood (mr PB)

Microglia replacement by microglia transplantation (Mr MT) in the adult mouse brain.

Stem Cells in Central Nervous System Diseases: Promising Therapeutic Strategies.

Restorative therapy using microglial depletion and repopulation for central nervous system injuries and diseases

Novel Microglia-based Therapeutic Approaches to Neurodegenerative Disorders

Evaluate the efficiency of Mr BMT in macrophage replacement of peripheral organs

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Correction: Novel Microglia-based Therapeutic Approaches to Neurodegenerative Disorders.

Microglia replacement effectively attenuates the disease progress of ALSP in the mouse model and human patient

Taming microglia: the promise of engineered microglia in treating neurological diseases

Human iPSC-derived Microglial Cells Integrated into Mouse Retina and Recapitulated Features of Endogenous Microglia

Progress and Challenges of Cell Replacement Therapy for Neurodegenerative Diseases Based on Direct Neural Reprogramming

Human-induced pluripotent stem cell-derived microglia integrate into mouse retina and recapitulate features of endogenous microglia

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

Microglial repopulation induced by PLX3397 protects against ischemic brain injury by suppressing neuroinflammation in aged mice

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets